BeiGene Head of R&D Lai Wang On Going Global
Executive Summary
The Chinese company's R&D leader discusses the US regulatory environment for Chinese-made drugs and implications for the cancer-focused company.
You may also be interested in...
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO argues, since payers will still be under pressure.
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO says.
Novartis/BeiGene Opt For PD-1/TIGIT Combo For NSCLC In US
The two companies have ceased to seek US approval for tislelizumab as a monotherapy for second-line non-small cell lung cancer and are instead seeming to pin their hopes on a combination with BeiGene’s anti-TIGIT antibody ociperlimab in the first-line setting.